^
    Back
    Association details:
    Biomarker:EGFR exon 20 insertion + TP53 G244A + SPTA1 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Clin Oncol Case Rep
    Title:

    Cetuximab Responsiveness in Patients with Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Alterations

    Published date:
    01/10/2022
    Excerpt:
    A 58-year-old non-smoking woman was diagnosed with metastatic NSCLC….Repeat biopsy showed a new EGFR exon 20 insertion...along with TP53 G244A and SPTA1 alterations. The patient was started on afatinib and cetuximab, with stable disease lasting nine months.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.4172/cocr.5(1).210